Decision Diagnostics Company Leadership
| DECN Stock | USD 0.0001 0.00 0.00% |
Decision Diagnostics employs about 6 people. The company is managed by 3 executives with a total tenure of roughly 20 years, averaging almost 6.0 years of service per executive, having 2.0 employees per reported executive. Analysis of Decision Diagnostics' management performance can provide insight into the firm performance.
| Keith Berman CEO CEO and President CFO, Principal Accounting Officer, Secretary, Treasurer and Director |
Decision Diagnostics Management Team Effectiveness
The company has return on total asset (ROA) of (0.2122) % which means that it has lost $0.2122 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (81.6052) %, meaning that it created substantial loss on money invested by shareholders. Decision Diagnostics' management efficiency ratios could be used to measure how well Decision Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 15th of February 2026, Return On Tangible Assets is likely to grow to -13.34. In addition to that, Return On Capital Employed is likely to grow to -2.48. At this time, Decision Diagnostics' Other Current Assets are very stable compared to the past year. As of the 15th of February 2026, Total Current Assets is likely to grow to about 2.5 M, while Total Assets are likely to drop about 5.2 M.As of the 15th of February 2026, Common Stock Shares Outstanding is likely to drop to about 284 M. In addition to that, Net Loss is likely to grow to about (25.4 M)Some institutional investors establish a significant position in stocks such as Decision Diagnostics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Decision Diagnostics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Decision Diagnostics Workforce Comparison
Decision Diagnostics is rated # 4 in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 258. Decision Diagnostics holds roughly 6.0 in number of employees claiming about 2.33% of equities under Health Care industry.
Decision Diagnostics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Decision Diagnostics Price Series Summation is a cross summation of Decision Diagnostics price series and its benchmark/peer.
Decision Diagnostics Notable Stakeholders
A Decision Diagnostics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Decision Diagnostics often face trade-offs trying to please all of them. Decision Diagnostics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Decision Diagnostics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Keith Berman | CEO and President CFO, Principal Accounting Officer, Secretary, Treasurer and Director | Profile | |
| Mark Krakauer | Head Efforts | Profile | |
| Chris Knapp | Consultant | Profile |
About Decision Diagnostics Management Performance
The success or failure of an entity such as Decision Diagnostics often depends on how effective the management is. Decision Diagnostics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Decision management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Decision management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (14.05) | (13.34) | |
| Return On Capital Employed | (2.61) | (2.48) | |
| Return On Assets | (4.72) | (4.49) | |
| Return On Equity | (70.55) | (67.03) |
Decision Diagnostics Workforce Analysis
Traditionally, organizations such as Decision Diagnostics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Decision Diagnostics within its industry.Decision Diagnostics Manpower Efficiency
Return on Decision Diagnostics Manpower
| Revenue Per Employee | 329.9K | |
| Revenue Per Executive | 659.7K | |
| Net Loss Per Employee | 4.9M | |
| Net Loss Per Executive | 9.9M |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Decision Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services. To learn how to invest in Decision Stock, please use our How to Invest in Decision Diagnostics guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Will Health Care Technology sector continue expanding? Could Decision diversify its offerings? Factors like these will boost the valuation of Decision Diagnostics. Projected growth potential of Decision fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Decision Diagnostics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.02) | Revenue Per Share | Quarterly Revenue Growth (0) | Return On Assets | Return On Equity |
Understanding Decision Diagnostics requires distinguishing between market price and book value, where the latter reflects Decision's accounting equity. The concept of intrinsic value - what Decision Diagnostics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Decision Diagnostics' price substantially above or below its fundamental value.
It's important to distinguish between Decision Diagnostics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Decision Diagnostics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Decision Diagnostics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.